Brief: Medigene Announces Global Collaboration With BioNTech To Advance T Cell Receptor Immunotherapies Against Cancer

Medigene AG

21/02/2022 18:24

Feb 21 (Reuters) - Medigene Ag  MDG1k.DE :
    * MEDIGENE AND BIONTECH ANNOUNCE GLOBAL COLLABORATION TO
ADVANCE T
CELL RECEPTOR IMMUNOTHERAPIES AGAINST CANCER
    * UNDER TERMS OF AGREEMENT, MEDIGENE WILL RECEIVE EUR 26
MILLION
UPFRONT, AS WELL AS RESEARCH FUNDING FOR PERIOD OF COLLABORATION
    * MEDIGENE - WILL CONTRIBUTE ITS PROPRIETARY TCR DISCOVERY
PLATFORM FOR DEVELOPMENT OF TCRS AGAINST MULTIPLE SOLID TUMOR
TARGETS NOMINATED BY BIONTECH
    * BIONTECH WILL ACQUIRE MEDIGENE'S NEXT GEN PRECLINICAL TCR
PROGRAM
    * BIONTECH WILL ALSO OBTAIN EXCLUSIVE OPTION TO ACQUIRE
ADDITIONAL
EXISTING TCRS IN MEDIGENE'S DISCOVERY PIPELINE
    * BIONTECH WILL ALSO RECEIVE LICENSES TO COMPANY'S PD1-41BB
SWITCH
RECEPTOR AND PRECISION PAIRING LIBRARY
    * WILL CONTINUE TO EVALUATE FINANCING OPTIONS SUCH AS
CAPITAL
MEASURES OR NEW PARTNERSHIPS
    * MEDIGENE - BIONTECH WILL BE RESPONSIBLE FOR GLOBAL
DEVELOPMENT &
HOLD EXCLUSIVE WORLDWIDE COMMERCIALIZATION RIGHTS ON TCR
THERAPIES FROM COLLABORATION
    * INITIAL TERM OF COLLABORATION IS THREE YEARS


 ((Reuters.Briefs@thomsonreuters.com;))